Treprostinil—one molecule over the course of disease

For the treatment of PAH (WHO Group 1), United Therapeutics offers a prostacyclin analog in a range of treprostinil formulations (oral, inhaled, and SC/IV)1-3

Start early with oral Orenitram for FC II/III adult patients to delay disease progression and improve exercise capacity Add Tyvaso (treprostinil inhalation) to background (ERA or PDE-5i) therapy in functional class III patients when inhaled delivery is most appropriate to improve exercise ability
Consider returning to Orenitram for functional class I/II hemodynamically stable Remodulin patients. Choose Remodulin PAH (WHO Group 1) patients to diminish symptoms associated with exercise and to diminish the rate of clinical deterioration in patients transitioning from Flolan® (epoprostenol sodium)
Consider returning to Orenitram for functional class I/II hemodynamically stable Remodulin patients. Start early with oral Orenitram for FC II/III adult patients to delay disease progression and improve exercise capacity
Add Tyvaso (treprostinil inhalation) to background (ERA or PDE-5i) therapy in functional class III patients when inhaled delivery is most appropriate to improve exercise ability
Choose Remodulin PAH (WHO Group 1) patients to diminish symptoms associated with exercise and to diminish the rate of clinical deterioration in patients transitioning from Flolan® (epoprostenol sodium)

ERA=endothelin receptor antagonist; FC=functional class; IV=intravenous; PAH=pulmonary arterial hypertension; PDE-5i=phosphodiesterase type 5 inhibitor; SC=subcutaneous; WHO=World Health Organization.

Stay with treprostinil across stages of PAH

  • VISIT THE
    ORENITRAM
    WEBSITE

  • VISIT THE
    TYVASO
    WEBSITE

  • VISIT THE
    REMODULIN
    WEBSITE

TREPROSTINIL

4 routes of administration for therapeutic customization1-3

EFFECTIVE
  • Clinical studies demonstrate efficacy across formulations1-3
FLEXIBLE
  • 1 molecule with 4 routes of administration1-3
  • Adaptive dosing to clinical effect and tolerability1-3
ESTABLISHED
  • Over 18 years of clinical experience3